I see. I got in on SENS at 4.95 then sold at 5.50. Only found months after everyone bought at below 2$. You think it is a long term hold? Seems like their valuation does not match their profits and I've read a lot of negative reviews about it in diabetes forums. Will it reach 10$ if the 180 day sensor is approved?
I'm not looking for penny stocks specifically, just want to get on the train before it leaves the platform. I don't want to get on at the final destination as has happened a few times.https://pennystocks.com/
But for me, I do a bit of research on something that I think will be a growing sector, such as Hydrogen Fuel Cell production, dig around and see if there is anything related in the micro-cap space, and park some money.
Another example is graphene production. This WILL rocket up at some point, but when? So poke around a little and see if you can find a micro-cap in the space you're interested in.
It's a longer term approach that can take years to yield returns, but occasionally you go to zero.
I don't think many of the Stonks folks really go for penny stocks though, so maybe that's why you didn't get any answers.
They aren't being cunts, it's just not their investment style.
Speaking of being a cunt... I'm avoiding work here atm, so I need to self-motivate
Didn't and now I'm up 8% lol.
It's hard to say. It will come down to their board of directors/CEO and marketing their product. Most CGM use are patients with Type 1 Diabetes of all ages, however Eversence (SENS) pretty much caters to just the adult Type 1 population. Currently at 90 days insertion/replacement in the U.S., but 180 days should get FDA approval (already approved in Europe). I also need to find out how much physicians (mainly Endocrinologists) will get paid for doing these outpatient procedures since they have to be willing to be trained to do it in order for patients to use it. Whereas other CGM use requires just simple training of the patient (that a CDE can do) to insert the sensor that are replaced every 10-14 days (Dexcom G6, Freestyle Libre 2, Medtronic Guardian). They have done clinical trials with the upcoming new insulin pump (iLet Bionic Panreas) to be used as a hybrid closed loop system. They will also eventually aim for 360 day sensor inservation/replacement. So sensor changes 1 x per year can be very attractive. All positive news that could help surge their stock in the long run, but will patients use it vs its competitors?
Get elected to Congress.
I agree with this. You still have to calibrate it 2x a day at least and it is not covered by insurance right now.
Yes, you can't forget about that. Zero calibration vs 2 mandatory fingerstick checks per day is not an easy sell. Dexcom G7 will be out later this year, with a 14 day disposable sensor with built in transmitter (no more separate transmitter). For Type 1's that use a insulin pump, the future is auto mode (closed loop system). Dexcom will be the biggest player for Omnipod and Tandem with Libre coming in second. Medtronic has their own package. Again a hard sell to patients. Zero calibration, 365 day insertion (that actually last the entire year) and more partnership with insulin pumps for closed loop use, then you could see rocket emoji's. By then the competition will have even greater products and maybe someone will truly break the code for a non-invasive CGM that has the accuracy and reliability of Dexcom, although doubtful. There is also microneedle CGM tech that shows promise.
